Drug Profile


Alternative Names: Azixa; EP-90745; MPC-6827; MX-128495; Veribulin

Latest Information Update: 23 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 31 Dec 2017 Immune Pharmaceuticals has patent protection for verubulin in USA, China, India, Japan and South Korea
  • 28 Jun 2016 Immune Pharmaceuticals files for patent protection with the US Patent and Trademark Office for Verubulin in combination with immune checkpoint inhibitors for the treatment of cancer in USA
  • 28 Jun 2016 Preclinical trials in Colorectal cancer (Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top